Public comment on draft guideline for clinical development of new diabetes medicines
「糖尿病の治療又は予防を目的とした新医薬品の臨床開発に関するガイドライン（案）」に関する御意見の募集について
Published: 2026-09-01 · Source: e-Gov Public Comment · Stage: Public Comment Closed · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Medium · Comment deadline: 2026-09-30 23:59 JST · First detected by this dashboard: 2026-09-03
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
A draft guideline on the clinical development of new medicines intended to treat or prevent diabetes was announced for public comment on 2026/09/01. The comment deadline is 2026/09/30 23:59, and the listed contact is the Pharmaceutical Evaluation and Management Division within the Pharmaceutical Safety Bureau, Ministry of Health, Labour and Welfare.
Business Impact
Developers of new medicines intended to treat or prevent diabetes may be affected because the draft concerns their clinical development; the provided information does not specify the proposed technical requirements.
Recommended Action
Reviewing the official Japanese consultation materials would help clarify the proposed clinical-development guidance and confirm the submission deadline and procedure.